Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
MediWound logo — The global leader in next-generation enzymatic therapeutics...

MediWound

The global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair

Founded 2000 Israel Israel 110 employees Post-IPO Equity Total: $152.65M Biotechnology, Manufacturing +1

General Information

Company Name MediWound
Founded Year 2000
Location Israel Israel
Employees 110
Industries Biotechnology, Manufacturing, Medical Devices
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with MediWound. To contact MediWound, visit mediwound.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a leading player in the field of next-generation enzymatic therapeutics, with a focus on non-surgical tissue repair. The company's flagship product, NexoBrid®, has garnered FDA approval as an orphan biologic for eschar removal in severe burns, offering a compelling alternative to surgical interventions and reducing associated costs and complications. Leveraging its core biotherapeutic enzymatic platform technology, MediWound has built a robust R&D pipeline, highlighted by EscharEx®, a Phase III-ready biologic designed for debridement of chronic wounds, and MW005 for the treatment of basal cell carcinoma. Founded in 2000 and headquartered in Israel, MediWound has also attracted significant investor attention. Its most recent investment round saw a $13.75M post-IPO equity investment by the European Innovation Council on 16 July 2024. The company's relentless pursuit of innovative biologics, coupled with a commitment to enhancing patient experiences and outcomes while reducing healthcare costs, positions it as a compelling player in the realms of biotechnology, manufacturing, and medical devices. For further information, please visit www.mediwound.com.

Taxonomy: enzymatic therapeutics, tissue repair, burns treatment, wound management, biologics development, FDA-approved drugs, clinical development, R&D pipeline, global commercialization, medical innovation, chronic wound therapy, topical therapeutics, phase III-ready drugs

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $2.50M 1
European Innovation Council
European Innovation Council
16 Jul 2024
Post IPO Equity $13.75M 1
European Innovation Council
European Innovation Council
16 Jul 2024
Post IPO Equity $25.00M 1
Molnlycke Health Care
15 Jul 2024
Grant $6.70M 1
Medical Technology Enterprise Consortium
28 Dec 2023
Post IPO Equity $27.50M 1
Point72
Point72
03 Feb 2023
Post IPO Equity $30.00M 4
Discount Capital Israel Biotech Fund New Era Capital Partners
Discount Capital, Israel Biotech Fund +2
22 Sep 2022
Grant $1.70M 1
U.S. Department of Defense
17 Feb 2022
Grant $5.50M 1
Biomedical Advanced Research and Development Authority (BARDA)
03 Mar 2020
Post IPO Equity $22.00M -
19 Sep 2017
Venture Round $18.00M 1
Clal Biotechnology Industries
Clal Biotechnology Industries
23 Jun 2013

MediWound Alternatives & Competitors

View All Alternatives
MediWound vs
Rexahn Pharmaceuticals
Rexahn Pharmaceuticals United States

TARGETING DIFFICULT TO TREAT CANCERS

Post-IPO Equity
7 employees
Biotechnology, Medical Devices
MediWound vs
Mainstay Medical
Mainstay Medical United States

First and Only FDA Approved Restorative Therapy for Chronic Mechanical Low Back Pain

IPO
183 employees
Biotechnology, Health Care
MediWound vs
Ascendant Biotech Corporation
Ascendant Biotech Corporation Thailand

Bringing Groundbreaking Technologies to the World

4 employees
Biotechnology, Health Care
View all alternatives

FAQ About MediWound

The global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair
MediWound was founded in 2000.
MediWound is headquartered in Israel.
MediWound operates in Biotechnology, Manufacturing and Medical Devices. Its work centres on enzymatic therapeutics, tissue repair, burns treatment and wound management.
MediWound has approximately 110 employees.
MediWound has completed 10 funding rounds, raising a total of $152.65M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to MediWound include Rexahn Pharmaceuticals, Mainstay Medical, Ascendant Biotech Corporation, Topica Pharmaceuticals, Wright Therapy Products. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MediWound and Rexahn Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MediWound, https://bouncewatch.com/company/mediwound, updated 2 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes